Highlights TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Market Closed - Euronext Paris Other stock markets 11:21:58 2024-05-02 am EDT			5-day change	1st Jan Change
0.2435 ^EUR	-4.51%		-5.07%	+5.87%

Apr. 25	TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 23	TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer	Apr. 23	CI
TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer	Apr. 02	CI
TME PHARMA : Invest Securities slightly adjusts its target	Apr. 02	CF
TME Pharma: green light from the FDA to launch a ph.II trial	Mar. 05	CF
TME Pharma N.V. Announces FDA Clearance of Investigational New Drug Application for Nox-A12 Phase 2 Trial in Brain Cancer	Mar. 05	CI
TME Pharma: end of convertible bond program	Feb. 09	CF
TME Pharma Raises EUR1.5 Million to Buy Back Convertible Bonds	Feb. 09	MT
TME Pharma Announces Successful Advice Meeting with US Food and Drug Administration on Nox-A12 Development in Brain Cancer	Jan. 09	CI
TME Pharma: shares fall after capital increase	Nov. 27	CF
TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-27	CI
TME Pharma N.V. Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer	23-10-10	CI
TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting	23-09-22	CI
Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer	23-09-13	CI
TME Pharma N.V. Provides Positive Data Update on Best Response to Therapy with First Complete Response in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near- Complete Response	23-07-13	CI
TME Pharma N.V. Announces Positive 15-Month Survival Data from Gloria Expansion Arm Evaluating NOX-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma	23-06-28	CI
TME Pharma N.V. Receives Investigational New Drug Approval for NOX-A12 From the US FDA	23-06-15	CI
TME Pharma N.V. Provides Positive Clinical Update and 14-Month Survival Data from Gloria Expansion Arm Evaluating Nox-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma	23-05-25	CI
TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-18	CI
TME Pharma N.V. Announces a Clinical Update on Survival of Newly Diagnosed Glioblastoma Patients in the GLORIA Expansion Arm Evaluating NOX-A12, TME Pharma’s CXCL12 Inhibitor	23-03-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Highlights

Filters